Pharmaids Pharmaceuticals Reports Mixed Financial Results Amid Sales Growth and Profitability Challenges in June 2025
Pharmaids Pharmaceuticals has announced its financial results for the quarter ending June 2025, showcasing significant growth in net sales at Rs 6.66 crore. However, challenges persist with a decline in profit before tax and operating profit, alongside an increased debt-equity ratio, indicating a complex financial landscape.
Pharmaids Pharmaceuticals has recently reported its financial results for the quarter ending June 2025, revealing a complex picture of performance within the microcap pharmaceuticals and biotechnology sector. The company achieved net sales of Rs 6.66 crore, marking a significant growth compared to the average of Rs 1.31 crore over the previous four quarters. This figure represents the highest sales recorded in the last five quarters, indicating a positive near-term sales trend.However, the financial results also highlight challenges for Pharmaids Pharmaceuticals. The profit before tax less other income (PBT) stood at Rs -7.21 crore, reflecting a notable decline compared to the average of Rs -4.32 crore from the previous four quarters. This trend suggests a negative outlook for profitability. Additionally, the company reported its lowest operating profit at Rs -5.41 crore and earnings per share (EPS) at Rs -1.40, both of which indicate declining profitability.
The debt-equity ratio has reached its highest level at 0.62 times, suggesting an increase in borrowings to support operations, which may impact liquidity. Overall, the evaluation changes reflect a nuanced financial landscape for Pharmaids Pharmaceuticals as it navigates both growth in sales and challenges in profitability.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
